My #1 Pre IPO Trade for 2025 – NAME and TICKER

One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...

David Hallal Biography and Net Worth

Director of AlloVir

David is a proven 30-year veteran in the biopharmaceutical industry, having grown and operated several successful biotechnology companies. During his 10-year tenure at Alexion Pharmaceuticals, where he served as Chief Executive Officer, Chief Operating Officer and Chief Commercial Officer, he led the pipeline expansion from a single-product to multi-product company, resulting in Alexion’s inclusion into the S&P500. Prior to Alexion, David spent nearly 20 years at Amgen, Biogen, and Eyetech in executive and senior leadership roles.

David also serves as Chairman and CEO of ElevateBio, an Independent Chairman of Scholar Rock (SRRK) and iTeos Therapeutics as well as an Independent Director of Seer. He holds a BA in psychology from the University of New Hampshire.

What is David Hallal's net worth?: The estimated net worth of David Hallal is at least $78,761.03 as of October 19th, 2022. Mr. Hallal owns 138,153 shares of AlloVir stock worth more than $78,761 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Hallal may own. Additionally, Mr. Hallal receives a salary of $254,380.00 as Director at AlloVir. Learn More about David Hallal's net worth.
How old is David Hallal?: Mr. Hallal is currently 58 years old. There are 7 older executives and no younger executives at AlloVir. The oldest executive at AlloVir is Mr. Vikas Sinha C.A., CPA, M.B.A., President, CFO & Director, who is 61 years old. Learn More on David Hallal's age.
What is David Hallal's salary?: As the Director of AlloVir, Inc., Mr. Hallal earns $254,380.00 per year. There are 3 executives that earn more than Mr. Hallal. The highest earning executive at AlloVir is Dr. Diana M. Brainard M.D., CEO & Director, who commands a salary of $978,990.00 per year. Learn More on David Hallal's salary.
How do I contact David Hallal?: The corporate mailing address for Mr. Hallal and other AlloVir executives is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. AlloVir can also be reached via phone at 617-433-2605 and via email at [email protected]. Learn More on David Hallal's contact information.
Has David Hallal been buying or selling shares of AlloVir?: David Hallal has not been actively trading shares of AlloVir over the course of the past ninety days. Most recently, David Hallal sold 600,000 shares of the business's stock in a transaction on Wednesday, October 19th. The shares were sold at an average price of $8.45, for a transaction totalling $5,070,000.00. Following the completion of the sale, the director now directly owns 138,153 shares of the company's stock, valued at $1,167,392.85. Learn More on David Hallal's trading history.
Who are AlloVir's active insiders?: AlloVir's insider roster includes Ercem Atillasoy (Insider), Jeffrey Bornstein (Director), Brett Hagen (CAO), David Hallal (Director), Morana Jovan-Embiricos (Director), Ann Leen (Insider), Agustin Melian (Insider), Jeroen Van Beek (Insider), Juan Vera (Director), and John Wilson (Director). Learn More on AlloVir's active insiders.
Are insiders buying or selling shares of AlloVir?: In the last year, insiders at the sold shares 53 times. They sold a total of 211,951 shares worth more than $149,284.16. The most recent insider tranaction occured on November, 19th when CAO Brett R Hagen sold 554 shares worth more than $304.70. Insiders at AlloVir own 33.8% of the company. Learn More about insider trades at AlloVir.
Information on this page was last updated on 11/19/2024.

David Hallal Insider Trading History at AlloVir

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/19/2022	Sell	600,000	$8.45	$5,070,000.00	138,153
9/29/2022	Sell	400,000	$7.35	$2,940,000.00	720,965
7/21/2022	Sell	4,227	$5.33	$22,529.91	2,073,662
4/21/2022	Sell	4,227	$5.87	$24,812.49	2,143,614
3/10/2022	Sell	40,481	$7.55	$305,631.55
1/24/2022	Sell	17,100	$8.01	$136,971.00

David Hallal Buying and Selling Activity at AlloVir

AlloVir Company Overview

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Today's Range

Now: $0.57

$0.56

$0.64

50 Day Range

MA: $0.78

$0.54

$1.01

2 Week Range

Now: $0.57

$0.52

$2.49

Volume

645,131 shs

Average Volume

617,220 shs

Market Capitalization

$65.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75

My #1 Pre IPO Trade for 2025 – NAME and TICKER

From Wyatt Investment Research | Ad

The Next SpaceX Pre-IPO

David Hallal Biography and Net Worth

What is David Hallal's net worth?

How old is David Hallal?

What is David Hallal's salary?

How do I contact David Hallal?

Has David Hallal been buying or selling shares of AlloVir?

Who are AlloVir's active insiders?

Are insiders buying or selling shares of AlloVir?